The absence of an effect on kidney oxygenation in non‐diabetic rodents or humans, despite a robust response on CKD progression in non‐diabetic patients in a recent trial, argues against the nephroprotective effects of SGLT2 inhibition being mediated by improved kidney oxygenation (Heerspink et al., 2020). Here, SLC5A2 is linked to chronic kidney disease.